SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
Commission File Number 0-27179
NOTIFICATION OF LATE FILING
(Check [ ] Form 10-KSB/A [ ] Form 11-K [ ] Form 20-F [X] Form 10-QSB
One): [ ] Form N-SAR
For Period Ended: December 31, 2003
---------------------------------------------------------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For the Transition Period Ended:
-----
READ ATTACHED INSTRUCTION SHEET BEFORE PREPARING FORM. PLEASE PRINT
OR TYPE.
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
-----------------------------------------------------
PART I. REGISTRANT INFORMATION
Full name of registrant BioSyntech, Inc.
--------------------------
Former name if applicable
------------------------
475 Boulevard Armand-Frappier,
- --------------------------------------------------------------------------------
Address of principal executive office (STREET AND NUMBER)
City, State and Zip Code Laval, Quebec, Canada H7V 4B3
--------------------------------------------------------
PART II. RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject amendment to the annual report, semi-annual report,
transition report on Form 10-KSB/A, 20-F, 11-K or Form N-SAR, or
portion thereof will be filed on or before the 15th calendar day
following the prescribed due date; or the subject quarterly report or
transition report on Form 10-QSB, or portion thereof will be filed on
or before the fifth calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART III. NARRATIVE
State below in reasonable detail the reasons why Form 10-KSB, 11-K,
20-F, 10-QSB, N-SAR or the transition report portion thereof could not be filed
within the prescribed time period. (Attach extra sheets if needed.)
The Registrant was unable to file the Form 10-QSB for the quarter ended
December 31, 2003 without unreasonable effort or expense due to delays in
gathering information for inclusion therein.
PART IV. OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Amine Selmani (450) 686-2437
- --------------------------------------------------------------------------------
(Name) (Area Code) (Telephone number)
(2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof? [ ] Yes [X] No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
BioSyntech, Inc.
(Name of registrant as specified in charter)
Has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date February , 17, 2004 By: /s/ Amine Selmani
---------------------------- ---------------------------------------
Name: Amine Selmani
Title: Chief Executive Officer & President
Instruction. The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant by an
authorized representative (other than an executive officer), evidence of
the representative's authority to sign on behalf of the registrant shall be
filed with the form.
